Results 201 to 210 of about 259,832 (291)

Recanalization of Thrombosed Atrial Flow Regulator in Failing Fontan: A Bridge to Transplant

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT We report the case of a 10‐year‐old boy (41 kg, 133 cm) with hypoplastic left heart syndrome (mitral and aortic atresia), who underwent staged palliation: Norwood‐Sano at 6 days, Glenn at 7 months, and Fontan completion at 3 years using a 16 mm non‐fenestrated extracardiac Gore‐Tex conduit.
Raymond N. Haddad, Estibaliz Valdeolmillos, Emre Belli, Sébastien Hascoët   +3 more
wiley   +1 more source

Understanding "Null Allele" in Renal Transplantation. [PDF]

Transplant Direct
Sulaiman S, Hafeeq B, Suhail Ediyangara Palliparamb M, Krishnakumar A, Khan MS, Aziz F.   +5 more
europepmc   +1 more source

STEROID WITHDRAWAL OR AVOIDANCE IN RENAL TRANSPLANT RECIPIENTS

, 2006
Tan Sy, S. H. Chang
openalex   +2 more sources

More Than a Question of Correlation: Characterization of the Evidentiary Basis for Biomarker Surrogates Used in European Marketing Authorizations

Clinical Pharmacology &Therapeutics, EarlyView.
Traditionally, clinical outcomes measuring how a patient feels, functions, or survives are preferred endpoints in clinical trials; however, some may take a long time to manifest in slowly developing diseases. Biomarkers, if properly validated, can serve as surrogate endpoints, acting as substitutes for clinical outcomes.
Renske Johanna Grupstra, Viktoriia Starokozhko, Elisabeth Bakker, Anna Maria Gerdina Pasmooij, Peter Gerardus Maria Mol   +4 more
wiley   +1 more source

Quantitative Train-of-Four Monitoring Using the TetraGraph™ to Evaluate Rocuronium Requirements During Renal Transplantation in a Pediatric Patient. [PDF]

J Med Cases
Nazir W, Villalobos EE, Paredes Padilla S, Maves G, Tobias JD.   +4 more
europepmc   +1 more source

A case of post renal transplant with episodes of acute abdomen pain

, 2013
Narayan Prasad
openalex   +1 more source

Safety, Pharmacokinetics, and Dose Recommendations for Nirmatrelvir/Ritonavir in Individuals with Mild to Moderate COVID‐19 and Severe Renal Impairment

Clinical Pharmacology &Therapeutics, EarlyView.
Patients with severe renal impairment and COVID‐19 are at high risk for severe disease and death. Nirmatrelvir/ritonavir, an antiviral therapy for COVID‐19, is eliminated by renal excretion and can accumulate in patients with severe renal impairment.
Jacqueline Gerhart, Candace R. Bramson, Michelle Goulding, Haihong Shi, Olayide Oladoyinbo, Phylinda L. S. Chan, Sunring Chime, Jennifer Hammond   +7 more
wiley   +1 more source

Timing of Transplant Surgery and Its Impact on Short- and Long-term Outcome After Renal Transplantation. [PDF]

Transplant Direct
Stellrecht KT, Daschner C, Windeler JJC, Jung M, Benck U, Schnülle P, Singer T, Gerken ALH, Vershenya S, Keese M, Schwenke K, Hocher B, Krüger B, Yazdani B, Kälsch AI, Jochims J, Krämer BK.   +16 more
europepmc   +1 more source

Th Clinical Effects of Sairei-to on Renal Transplanted Patients with Proteinuria.

, 1995
Seiji Kunikata, Tokumi Ishii, Takahiro Akiyama, Takashi Kurita   +3 more
openalex   +2 more sources